
|Podcasts|September 27, 2021
Highlighting results from first FDA-reported study for treatment of presbyopia
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Advertisement
Listen to the findings from the first FDA-reported study of a presbyopia-treatment eye drop.
George O. Waring IV, MD, FACS, of the Waring Vision Institute (Mount Pleasant, SC), discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Watch the interview:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
3
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
4
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
5























